Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study (MEMORY)
A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study
調査の概要
詳細な説明
Asthma with eosinophilic inflammation in the airways and/or blood eosinophilia is associated with clinical severity including the risk of exacerbations and relevant comorbidities (e.g. nasal polyposis). Interleukin-5 (IL-5) is a cytokine essential for eosinophil trafficking and survival. Clinical trials of blocking IL-5 with anti-IL-5 antibodies (mepolizumab and reslizumab) in patients with uncontrolled eosinophilic asthma resulted in an improvement in exacerbation rate and oral corticosteroid use. In some studies with mepolizumab and reslizumab there was a beneficial effect on lung function (FEV1). In addition, many patients described a profound impact on asthma symptoms and quality of life in personal reports which is not uniformly reflected in clinical trials.
The MEMORY trial is the first to primarily evaluate the effect of mepolizumab treatment on pulmonary function in patients with severe eosinophilic asthma. Importantly, using spirometry and bodyplethysmography will allow to evaluate additional parameters beyond FEV1 that more closely mirror the pathophysiological changes and functional aspects of airflow limitation in asthma in real life, e.g. airway resistance, hyperinflation and diffusion capacity. The proposed trial will answer the important questions: if, and if so, which parameters of airway (patho-) physiology as assessed by bodyplethysmography best reflect clinical response to mepolizumab therapy in patients with severe eosinophilic asthma. In addition, the time course to clinical response will be assessed. Equally important, there is only a loose correlation between FEV1 and parameters of asthma control and asthma-related quality of life. This is why another new and important aspect of this trial is to carefully monitor asthma control and asthma quality in life in correlation with lung function changes beyond FEV1. Finally, it is tempting to speculate that the proposed trial will contribute to the question how to best define clinical response to mepolizumab.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Mainz、ドイツ、55131
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Pneumologie
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients must be able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form.
- Male or female patients at least 18 years
- Physician-diagnosis of asthma and evidence of asthma as documented by either reversibility of airflow obstruction (FEV1 ≥ 12% or 200 ml) demonstrated at visit 1 or visit 2 .
- ICS dose must be ≥ 1000 μg/day BDP or equivalent daily with or without maintenance oral corticosteroids.
- Treatment in the past 12 months with an additional controller medication for at least 3 successive months, e.g., long-acting beta-2-agonist (LABA), leukotriene receptor antagonist (LTRA), or theophylline.
- Persistent airflow obstruction as indicated by a pre-bronchodilator FEV1 < 80% predicted recorded at Visit 1 or < 90% for patients on oral corticosteroids.
- An elevated peripheral blood eosinophil level of ≥ 300/µL that is related to asthma or ≥ 150/µL in patients treated with oral corticosteroids as maintenance therapy demonstrated at visit 1 or in the previous 12 months
- Confirmed history of two or more exacerbations requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral), in the 12 months prior to visit 1, despite the use of high-dose inhaled corticosteroids. For patients receiving maintenance corticosteroids, the corticosteroid treatment for the exacerbations must have been a two-fold increase or greater in the dose.
Exclusion Criteria:
- Current smokers or former smokers with a smoking history of ≥ 10 pack years (number of pack years = (number of cigarettes per day / 20) x number of years smoked). Patients who have not smoked for ≥ 6 months before visit 1 and have < 10 pack years can be included into the study.
- Presence of a clinically important lung condition other than asthma. This includes current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer.
- Patients who have received omalizumab [Xolair] within 130 days of Visit 1.
- Patients who have received any biological to treat inflammatory disease within 5 half-lives of visit 1
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Mepolizumab
100 mg SC every 4 weeks for 13 injections
|
100 mg SC every 4 weeks for 13 injections
|
実験的:Placebo
Amount of Placebo corresponding to mepolizumab dose SC every 4 weeks for 13 injections
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
mean change from baseline in pre- and post-bronchodilator FVC at visit 10 (week 24) and at time of response
時間枠:week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator forced vital capacity (FVC) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
mean change from baseline in pre- and post-bronchodilator FEV1 at visit 10 (week 24) and at time of response
時間枠:week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
mean change from baseline in pre- and post-bronchodilator RV at visit 10 (week 24) and at time of response
時間枠:week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator residual volume (RV) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
mean change from baseline in pre- and post-bronchodilator TLC at visit 10 (week 24) and at time of response
時間枠:week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator total lung capacity (TLC) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
mean change from baseline in pre- and post-bronchodilator airway resistance at visit 10 (week 24) and at time of response
時間枠:week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator airway resistance at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
mean change from baseline in pre- and post-bronchodilator IC at visit 10 (week 24) and at time of response
時間枠:week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator inspiratory capacity (IC) at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
mean change from baseline in pre- and post-bronchodilator CO diffusion capacity at visit 10 (week 24) and at time of response
時間枠:week 24 and time of response
|
The primary outcome is the mean change from baseline in pre- and post-bronchodilator CO diffusion capacity at visit 10 (week 24) and at time of response
|
week 24 and time of response
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Mean change from baseline in pre- and post-bronchodilator forced vital capacity (FVC) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
時間枠:1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
Mean change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
時間枠:1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
Mean change from baseline in pre- and post-bronchodilator residual volume (RV) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
時間枠:1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
Mean change from baseline in pre- and post-bronchodilator total lung capacity (TLC) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
時間枠:1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
Mean change from baseline in pre- and post-bronchodilator airway resistance over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
時間枠:1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
Mean change from baseline in pre- and post-bronchodilator inspiratory capacity (IC) over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
時間枠:1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
Mean change from baseline in pre- and post-bronchodilator CO diffusion capacity over the 48-week treatment period at prespecified timepoints (1, 3, 6, 9 and 12 months)
時間枠:1, 3, 6, 9 and 12 months
|
1, 3, 6, 9 and 12 months
|
|
Exercise tolerance in a subgroup of patients: Mean change from baseline in exercise endurance time
時間枠:1, 3, 6, 9 and 12 month
|
Mean change from baseline in exercise endurance time during a sub-maximal constant-load cycle ergometry test after 1, 3, 6, 9 and 12 months of treatment.
|
1, 3, 6, 9 and 12 month
|
Exercise tolerance in a subgroup of patients: Mean change from baseline in inspiratory capacity (IC)
時間枠:1, 3, 6, 9 and 12 month
|
Mean change from baseline in inspiratory capacity (IC) at rest and at peak during sub-maximal constant-load cycle ergometry test after 1, 3, 6, 9 and 12 months of treatment.
|
1, 3, 6, 9 and 12 month
|
Exercise tolerance in a subgroup of patients: Mean change from baseline in exertional dyspnea and leg discomfort (Borg CR10 Scale®)
時間枠:1, 3, 6, 9 and 12 month
|
Mean change from baseline in exertional dyspnea and leg discomfort (Borg CR10 Scale®) during sub-maximal constant-load cycle ergometry test after 1, 3, 6, 9 and 12 months of treatment
|
1, 3, 6, 9 and 12 month
|
Time to clinical response and time to change of baseline parameters of clinical Response: sence of smell
時間枠:52 weeks
|
52 weeks
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: sense of taste
時間枠:52 weeks
|
52 weeks
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: lung volume
時間枠:52 weeks
|
52 weeks
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: CO Diffusion capacity
時間枠:52 weeks
|
52 weeks
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: FEV1 reversibility
時間枠:52 weeks
|
52 weeks
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: exhaled NO (eNO)
時間枠:52 weeks
|
52 weeks
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: blood eosinophils
時間枠:52 weeks
|
52 weeks
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: eosinophilic cationic Protein (ECP)
時間枠:52 weeks
|
52 weeks
|
|
Time to clinical response and time to change of baseline parameters of clinical Response: blood periostin
時間枠:52 weeks
|
52 weeks
|
|
Mean change from baseline in Asthma Control Questionnaire (ACQ)
時間枠:52 weeks
|
52 weeks
|
|
Mean change from baseline in Asthma Quality of Life Questionnaire (AQLQ)
時間枠:52 weeks
|
52 weeks
|
|
Mean change from baseline in St. George´s Respiratory Questionnaire (SQRG)
時間枠:52 weeks
|
52 weeks
|
|
Mean change from baseline in Dyspnoe Index (BDI/TDI)
時間枠:52 weeks
|
52 weeks
|
|
Mean change from baseline in fatique
時間枠:52 weeks
|
52 weeks
|
|
Mean change from baseline in number of days off school/work over the 48-week treatment period
時間枠:48 weeks
|
48 weeks
|
|
Time to first clinically significant exacerbation requiring oral or systemic corticosteroids, hospitalization, and/or emergency department (ED) visits
時間枠:52 weeks
|
52 weeks
|
|
Frequency of clinically significant exacerbations
時間枠:52 weeks
|
52 weeks
|
|
Time to first exacerbation requiring hospitalization or emergency department (ED) visit
時間枠:52 weeks
|
52 weeks
|
|
Frequency of exacerbations requiring hospitalization (including intubation and admittance to an intensive care unit (ICU)) or ED visits
時間枠:52 weeks
|
52 weeks
|
|
GETE rating by physician and patient at time of response and over the 52-week treatment period at pre-specified timepoints (1, 3, 6, 9 and 12 months)
時間枠:1, 3, 6, 9 and 12 month
|
1, 3, 6, 9 and 12 month
|
|
Mean change in proportion of patients with nasal polyps, chronic sinusitis and loss of smell and taste
時間枠:52 weeks
|
52 weeks
|
|
Clinical response to mepolizumab in relation to asthma parameters which potentially predict clinical response
時間枠:52 weeks
|
Clinical response to mepolizumab in relation to asthma parameters which potentially predict clinical response (age at onset and duration of asthma, prior asthma medication, presence of nasal polyps, sense of smell and taste, allergic sensitization (skin prick test, total and specific IgE against aeroallergens and Staph.
aureus enterotoxin), reversibility of airflow obstruction, eNO, blood eosinophils, eosinophilic cationic protein (ECP), blood periostin, ANA, ANCA, ECP.
|
52 weeks
|
Routine safety assessment (AE and SAE reporting, withdrawals, pregnancy, hematological and clinical chemistry parameters, ECG and vital signs (pulse rate and systolic and diastolic blood pressure))
時間枠:52 weeks
|
Routine safety assessments are incorporated throughout and/or at the end of treatment period including AE and SAE reporting, withdrawals, pregnancy, hematological and clinical chemistry parameters, ECG and vital signs (pulse rate and systolic and diastolic blood pressure).
|
52 weeks
|
協力者と研究者
協力者
捜査官
- 主任研究者:Stephanie Korn, MD、Johannes Gutenberg University Mainz
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
プラセボの臨床試験
-
Palacky University完了
-
Universidade Federal do ParaConselho Nacional de Desenvolvimento Científico e Tecnológico完了
-
Advice Pharma Group srl積極的、募集していない肥満 | 栄養障害 | 体重 | 減量 | 食生活 | 太りすぎと肥満 | 健康行動 | ダイエット、健康 | ダイエット習慣 | ライフスタイル | 栄養、健康 | 行動障害イタリア
-
University Hospital, Strasbourg, France積極的、募集していない